Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
The story does a good job of pointing out one advantage of the pill approach compared to delivery via colonoscopythe reduced cost. "There was a significant difference in cost. Though the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300." This was a close call. Early on, it says the pill was 90% effective for treating recurrentClostridium difficile infections. Later on, the story explains that both were equally successful in treating the Clostridium difficile infections. It would take a bit of deduction to figure out that the 90% treatment rate applies to both the pills and colonoscopies. And the study puts this figure close to 96%. But we'll give the benefit of the doubt and rate it satisfactory. The story gets a satisfactory here for including the differences between the two methods of delivery: One source is quoted saying, "colonoscopies and the anesthesia required for the procedure can put a lot of stress on a person's bodyand can be complicated for the people most at risk for C. difficile infections." It could have gone a step further and reminded readers that a colonoscopy is an invasive procedure with the inherent risks of infection and perforation that obviously aren't there when taking a pill. The story did not mention the other adverse events described in the paper such as nausea and vomiting, though. The story comments on the size of the study and quotes a researcher about strengths (a randomized, controlled trial) and limitations (selection bias) of the study. Selection bias, in this case, means many people were excluded from the clinical trial if they had any number of issues (patients with severe or complicated cases were excluded, for example), potentially biasing the results. In a more real-world setting, the effectiveness rate may drop once it's tried on a wider range of people. No disease mongering here. The story does include comments from an independent source unaffiliated with the research. But, it doesn't specify that the source has received research money from a drug company that's developing microbiome drugs. Standard treatment for C. diff is antibiotics. This should have been mentioned. Unfortunately, the story doesn't spell out whether the pill form FMT is now, or soon will be, available to the public. The story does mention that numerous other clinical trials are using FMT as a possible treatment for various diseases but it is unclear whether the pill form is an option for physicians at this point. What's new here is that a pill form for delivery of a fecal transplant is being tested against a colonoscopy. The story established this. It does not appear to rely on a news release.

Ex Output:
Fecal transplant via a pill? Newsweek's coverage points out possible selection bias of study participants

Ex Input:
The study to be published on Wednesday in the Journal of Neuroscience differs from many other pot-related research projects that are focused on chronic, heavy users of cannabis. The collaborative effort between Northwestern University's medical school, Massachusetts General Hospital and Harvard Medical School showed a direct correlation between the number of times users smoked and abnormalities in the brain. "What we're seeing is changes in people who are 18 to 25 in core brain regions that you never, ever want to fool around with," said co-senior study author Dr. Hans Beiter, professor of psychiatry and behavioral sciences at Northwestern University. In particular, the study identified changes to the nucleus accumbens and the nucleus amygdala, regions of the brain that are key to regulating emotion and motivation, in marijuana users who smoke between one and seven joints a week. The researchers found changes to the volume, shape and density of those brain regions. But more studies are needed to determine how those changes may have long-term consequences and whether they can be fixed with abstinence, Beiter said. "Our hypothesis from this early work is that these changes may be an early sign of what later becomes amotivation, where people aren't focused on their goals," he said. The study, which was funded in part by the National Institute on Drug Abuse and the White House Office of National Drug Control Policy, comes as access to pot is expanding following 2012 votes in Washington state and Colorado to legalize its recreational use. The drug remains illegal under federal law. Medical pot is allowed in 20 U.S. states. Pot legalization advocates make the argument that marijuana is safer than alcohol a central part of their campaigns. Other research has found drinking alcohol alters the brain, Beiter said. But while researchers do not know exactly how the mental rewiring seen in pot users affects their lives, the study shows it physically changes the brain in ways that differ from drinking, he said. This latest study fits with other research showing marijuana use has significant effects on young people because their brains are still developing, and Beiter said he has become convinced that marijuana should only be used by people under 30 if they need it to manage pain from a terminal illness.

Ex Output:
Casual pot use causes brain abnormalities in the young: study.

Ex Input:
The lawsuit marks the first multi-plaintiff trial in the litigation over whether glyphosate, Roundup's active ingredient, is carcinogenic, and is the first trial outside of California. It is being held in St. Louis, where Monsanto was headquartered before Bayer bought the company in a $63 billion deal in 2018. Three consecutive juries found the company liable for causing cancer with damages of tens of millions of dollars awarded to each plaintiff. Bayer is appealing those verdicts. Court-appointed mediator Ken Feinberg has put the number of Roundup cancer claimants at more than 75,000 while Bayer said the claims it has been served with in court were below 50,000. Bayer's share price has tumbled since the first verdict in August 2018 but the stock rose 3% on Friday after Bloomberg reported a possible out-of-court settlement with some plaintiffs that could lead to a total payout of about $10 billion. While traders said the market likes the idea of Bayer settling the litigation, some cautioned that the prospect of a comprehensive deal remained uncertain. Analysts have estimated the size of any such settlement at $8-$12 billion. While most plaintiffs' lawyers have agreed to postpone trials pending negotiations, some have decided to pursue their clients' day in court. The case in Missouri's Circuit Court for the 22nd Judicial Circuit of the City of St. Louis is scheduled to last several weeks, with both sides presenting extensive scientific evidence through expert witnesses. Bayer denies all allegations that Roundup or glyphosate causes cancer, saying decades of independent studies have shown the world's most widely used weed killer to be safe for human use and noting that regulators around the world have approved the product. "At the end of the day, this trial should come down to the weight of the science, and we remain confident in the extensive scientific record and regulatory assessments that support the safety of our glyphosate-based herbicides and that they do not cause cancer," the company said in a statement. Several court cases have been postponed by both parties in the past to expedite settlement talks. By pursuing the St. Louis trail The Miller Firm LLC, a key player in the litigation, is seeking to increase pressure on Bayer. The case involves the claims of Bryce Batiste from Louisiana, Ann Meeks from Florida, Glen Ashelman from Pennsylvania and Christopher Wade, a St. Louis resident. All four have been diagnosed with non-Hodgkin's lymphoma, a blood cell cancer that plaintiffs in the litigation allege is caused by Roundup. Some legal experts said Bayer could benefit from a home advantage in the St. Louis trial, where Monsanto has century-old roots. But juries in the city are also known to dole out massive damages awards against large corporations.

Ex Output:
Bayer faces fourth U.S. Roundup cancer trial in Monsanto's hometown.